The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Physical Health Monitoring of Patients With Schizophrenia
Abstract
OBJECTIVE: Schizophrenia is associated with several chronic physical illnesses and a shorter life expectancy, compared with life expectancy in the general population. One approach to improving the health of patients with schizophrenia is to improve the monitoring of physical health that occurs in psychiatric settings. The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings. METHOD: A consensus meeting including psychiatric and other medical experts assembled on October 17-18, 2002, to evaluate the existing literature and to develop recommendations for physical health monitoring of patients with schizophrenia. Conference participants reviewed the literature in the following areas: 1) weight gain and obesity; 2) diabetes; 3) hyperlipidemia; 4) prolongation of the QT interval on the ECG; 5) prolactin elevation and related sexual side effects; 6) extrapyramidal side effects, akathisia, and tardive dyskinesia; 7) cataracts; and 8) myocarditis. Experts for each topic area formulated monitoring recommendations that were discussed by all of the participants until a consensus was reached. RESULTS: Consensus recommendations included regular monitoring of body mass index, plasma glucose level, lipid profiles, and signs of prolactin elevation or sexual dysfunction. Information from monitoring should guide the selection of antipsychotic agents. Specific recommendations were made for cardiac monitoring of patients who receive medications associated with QT interval prolongation, including thioridazine, mesoridazine, and ziprasidone, and for monitoring for signs of myocarditis in patients treated with clozapine. Patients who receive both first- and second-generation antipsychotic medications should be examined for extrapyramidal symptoms and tardive dyskinesia. Patients with schizophrenia should receive regular visual examinations. CONCLUSIONS: The conference participants recommended that mental health care providers perform physical health monitoring that typically occurs in primary care settings for their patients who do not receive physical health monitoring in those settings. This change in usual practice is recommended on the basis of the conference participants' belief that this additional monitoring will result in the earlier detection of common, serious risk factors that could, without detection and intervention, contribute to impaired health of patients with schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
(1998) · PsycEXTRA Dataset · doi:10.1037/e565682010-001 · Cited by 9,472
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Serum Cholesterol, Lipoproteins, and the Risk of Coronary Heart Disease: The Framingham Study
KANNEL, W. B., CASTELLI, W. P., GORDON, T., & MCNAMARA, P. M. (1971) · Annals of Internal Medicine · doi:10.7326/0003-4819-74-1-1 · Cited by 2,057
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Self-citationDopamine as a Prolactin (PRL) Inhibitor
Ben-Jonathan, N., & Hnasko, R. (2001) · Endocrine Reviews · doi:10.1210/edrv.22.6.0451 · Cited by 983 · cited 1×
“Antipsychotic medications— particularly first-generation agents and risperidone—can cause hyperprolactinemia by their activity at dopamine D2 receptors that suppress the secretory activity of pituitary lactotrophs (52).”
BackgroundFeldman, A. M., & McNamara, D. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431908 · Cited by 958
Janssen, I., Katzmarzyk, P. T., & Ross, R. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2074 · Cited by 957
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death
Glassman, A. H., & Bigger, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1774 · Cited by 822
Self-citationArvanitis, L. A., & Miller, B. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00190-x · Cited by 803
Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study
Henderson, D. C., Cagliero, E., Gray, C., Nasrallah, R. A., Hayden, D. L., Schoenfeld, D. A., & Goff, D. C. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.6.975 · Cited by 701
Jeppesen, J. Ø., Hein, H. O., Suadicani, P., & Gyntelberg, F. (1998) · Circulation · doi:10.1161/01.cir.97.11.1029 · Cited by 676
The Treatment of Unrelated Disorders in Patients with Chronic Medical Diseases
Redelmeier, D. A., Tan, S. H., & Booth, G. L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805213382106 · Cited by 635
Association of Diabetes Mellitus With Use of Atypical Neuroleptics in the Treatment of Schizophrenia
Sernyak, M. J., Leslie, D. L., Alarcon, R. D., Losonczy, M. F., & Rosenheck, R. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.4.561 · Cited by 623
Antipsychotic-induced weight gain: a review of the literature.
Allison, D. B., & Casey, D. E. (2001) · PubMed · Cited by 595
Self-citationWhy Do Schizophrenic Patients Refuse to Take Their Drugs?
Van Putten, T. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760130049008 · Cited by 572
Prevalence and Correlates of Diabetes in National Schizophrenia Samples
Dixon, L., Weiden, P., Delahanty, J., Goldberg, R., Postrado, L., Lucksted, A., & Lehman, A. (2000) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033504 · Cited by 569
Galactorrhea: A Study of 235 Cases, Including 48 with Pituitary Tumors
Kleinberg, D. L., Noel, G. L., & Frantz, A. G. (1977) · New England Journal of Medicine · doi:10.1056/nejm197703172961103 · Cited by 560
Self-citationLaRosa, J. C., Hunninghake, D., Bush, D., Criqui, M. H., Getz, G. S., Gotto, A. M., Grundy, S. M., Rakita, L., Robertson, R. M., & Weisfeldt, M. L. (1990) · Circulation · doi:10.1161/01.cir.81.5.1721 · Cited by 556
Myocarditis and cardiomyopathy associated with clozapine
Kilian, J. G., Kerr, K., Lawrence, C., & Celermajer, D. S. (1999) · The Lancet · doi:10.1016/s0140-6736(99)10385-4 · Cited by 544
Novel antipsychotics: comparison of weight gain liabilities.
Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999) · PubMed · Cited by 523
Self-citationLindenmayer, J.-P., Czobor, P., Volavka, J., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.2.290 · Cited by 465
Self-citationKoro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L., Kreyenbuhl, J., Revicki, D., & Buchanan, R. (2002) · BMJ · doi:10.1136/bmj.325.7358.243 · Cited by 421
Self-citationVolavka, J., Czobor, P., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., Cooper, T. B., Chakos, M., & Lieberman, J. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.2.255 · Cited by 407
Self-citationNovel Antipsychotics: Comparison of Weight Gain Liabilities
Wirshing, D. A., Wirshing, W. C., Kysar, L., Berisford, M. A., Goldstein, D., Pashdag, J., Mintz, J., & Marder, S. R. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0602 · Cited by 393
Self-citationThe Distribution of Body Mass Index Among Individuals With and Without Schizophrenia
Allison, D. B., Fontaine, K. R., Heo, M., Mentore, J. L., Cappelleri, J. C., Chandler, L. P., Weiden, P. J., & Cheskin, L. J. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0402 · Cited by 390
Mortality in a Cohort of Patients with Schizophrenia: A Record Linkage Study*
Newman, S. C., & Bland, R. C. (1991) · The Canadian Journal of Psychiatry · doi:10.1177/070674379103600401 · Cited by 371
Conley, R. R., & Mahmoud, R. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.5.765 · Cited by 334
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001) · PubMed · Cited by 317
Prolactin Levels and Adverse Events in Patients Treated with Risperidone
Kleinberg, D. L., Davis, J. M., de Coster, R., Van Baelen, B., & Brecher, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00011 · Cited by 307
Self-citation(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.6.782 · Cited by 306
Melkersson, K. I., Hulting, A.-L., & Brismar, K. E. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1006 · Cited by 299
The Effects of Novel Antipsychotics on Glucose and Lipid Levels
Wirshing, D. A., Jennifer A., J. A., Meng, L. R., Ballon, J. S., Marder, S. R., & Wirshing, W. C. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1002 · Cited by 294
Self-citationLong-Term Olanzapine Treatment: Weight Change and Weight-Related Health Factors in Schizophrenia
Kinon, B. J., Basson, B. R., Gilmore, J. A., & Tollefson, G. D. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0204 · Cited by 269
Meyer, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0509 · Cited by 267
Tardive Dyskinesia: Prevalence, Incidence, and Risk Factors
KANE, J. M., WOERNER, M., & LIEBERMAN, J. (1988) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198808001-00010 · Cited by 266
Self-citationAntipsychotic Metabolic Effects: Weight Gain, Diabetes Mellitus, and Lipid Abnormalities
McIntyre, R. S., McCann, S. M., & Kennedy, S. H. (2001) · The Canadian Journal of Psychiatry · doi:10.1177/070674370104600308 · Cited by 261
David, S. R., Taylor, C. C., Kinon, B. J., & Breier, A. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)80086-7 · Cited by 237
Koro, C. E., Fedder, D. O., L'Italien, G. J., Weiss, S., Magder, L. S., Kreyenbuhl, J., Revicki, D., & Buchanan, R. W. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.11.1021 · Cited by 234
Self-citationOlanzapine Increases Weight and Serum Triglyceride Levels
Osser, D. N., Najarian, D. M., & Dufresne, R. L. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1109 · Cited by 229
Tests of Glycemia for the Diagnosis of Type 2 Diabetes Mellitus
Barr, R. G., Nathan, D. M., Meigs, J. B., & Singer, D. E. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-4-200208200-00011 · Cited by 215
The Effects of Antipsychotic-Induced Hyperprolactinaemia on the Hypothalamic-Pituitary-Gonadal Axis
Smith, S., Wheeler, M. J., Murray, R., & O’Keane, V. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200204000-00002 · Cited by 202
Dopamine Antagonists and the Development of Breast Cancer
Wang, P. S., Walker, A. M., Tsuang, M. T., Orav, E. J., Glynn, R. J., Levin, R., & Avorn, J. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.12.1147 · Cited by 196
Elevation of Prolactin Levels by Atypical Antipsychotics
Turrone, P., Kapur, S., Seeman, M. V., & Flint, A. J. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.133 · Cited by 190
Prospective Study of Tardive Dyskinesia Incidence in the Elderly
Saltz, B. L. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470170090030 · Cited by 183
Azorin, J.-M., Spiegel, R., Remington, G., Vanelle, J.-M., Péré, J.-J., Giguere, M., & Bourdeix, I. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.8.1305 · Cited by 179
Novel Antipsychotics and Severe Hyperlipidemia
Meyer, J. M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200108000-00003 · Cited by 168
Droperidol Causes a Dose-dependent Prolongation of the QT Interval
Lischke, V., Behne, M., Doelken, P., Schledt, U., Probst, S., & Vettermann, J. (1994) · Anesthesia & Analgesia · doi:10.1213/00000539-199411000-00028 · Cited by 162
Myocarditis and Cardiomyopathy Associated with Clozapine Use in the United States
Grenade, L. L., Graham, D., & Trontell, A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107193450317 · Cited by 161
Neuroleptic-induced hyperprolactinemia
Dickson, R. A., & Glazer, W. M. (1999) · Schizophrenia Research · doi:10.1016/s0920-9964(98)00159-5 · Cited by 161
Changes in body mass index for individuals with and without schizophrenia, 1987–1996
Homel, P., Casey, D., & Allison, D. B. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00256-0 · Cited by 160
Self-citationA Program for Treating Olanzapine-Related Weight Gain
Ball, M. P., Coons, V. B., & Buchanan, R. W. (2001) · Psychiatric Services · doi:10.1176/appi.ps.52.7.967 · Cited by 158
Self-citationDifferential effect of clozapine on weight: a controlled study
Bustillo, J., Buchanan, R. W., Irish, D., & Breier, A. F. (1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.6.817 · Cited by 157
Self-citationThe Mount Sinai Conference on the Pharmacotherapy of Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Davis, J. M., Kane, J. M., Lieberman, J. A., & Schooler, N. R. (2002) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a006926 · Cited by 127
Self-citationMelkersson, K. I., Hulting, A., & Brismar, K. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n1112 · Cited by 125
Review of quetiapine and its clinical applications in schizophrenia
Kasper, S. F., & Müller-Spahn, F. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.4.783 · Cited by 110
Спивак, Б., Roitman, S., Vered, Y., et al. (1998) · PubMed · Cited by 97
Neuroleptic-induced Prolactin Level Elevation and Breast Cancer
Schyve, P. M. (1978) · Archives of General Psychiatry · doi:10.1001/archpsyc.1978.01770350017001 · Cited by 97
Clozapine Use and Risk of Diabetes Mellitus
Wang, P. S., Glynn, R. J., Ganz, D. A., Schneeweiß, S., Levin, R., & Avorn, J. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200206000-00002 · Cited by 90
Neuroleptic treatment and other factors modifying cancer risk in schizophrenic patients
Mortensen, P. B. (1987) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1987.tb02839.x · Cited by 87
Serum triglyceride levels in patients treated with clozapine
Ghaeli, P., & Dufresne, R. L. (1996) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/53.17.2079 · Cited by 85
Pignone, M. P., Phillips, C. J., Atkins, D., Teutsch, S. M., Mulrow, C. D., & Lohr, K. N. (2001) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(01)00255-0 · Cited by 84
Windgassen, K., Wesselmann, U., & Mönking, H. S. (2008) · Neuropsychobiology · doi:10.1159/000119265 · Cited by 67
Atypical Antipsychotic Drug Use and Diabetes
Ananth, J., Venkatesh, R., Burgoyne, K. S., & Gunatilake, S. (2002) · Psychotherapy and Psychosomatics · doi:10.1159/000064807 · Cited by 59
Are Schizophrenia or Antipsychotic Drugs a Risk Factor for Cataracts?
Ruigómez, A., Rodríguez, L. A. G., Dev, V., Arellano, F. M., & Raniwala, J. (2000) · Epidemiology · doi:10.1097/00001648-200011000-00002 · Cited by 47
Management of weight gain in patients with schizophrenia.
Aquila, R. (2002) · PubMed · Cited by 40
Ziprasidone: profile on safety
Goodnick, P. J. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.10.1655 · Cited by 30
Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients
Eşel, E., Baştürk, M., Gönül, A. S., Kula, M., Turan, M., Yabanoğlu, İ., & Sofuoǧlu, S. (2001) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(01)00016-6 · Cited by 21
Cited by
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
McEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., Meltzer, H. Y., Hsiao, J., Scott Stroup, T., & Lieberman, J. A. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.014 · Cited by 1,140
Self-citation
Metadata
- Authors
- Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., Stroup, S., Weissman, E. M., Wirshing, D. A., Hall, C. S., Pogach, L., Pi-Sunyer, X., Bigger, J. T., Friedman, A., Kleinberg, D., Yevich, S. J., Davis, B., & Shon, S.
- Venue
- American Journal of Psychiatry
- Published
- 2004-08-01
- Volume
- 161
- Issue
- 8
- Pages
- 1334-1349
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2101762862
- Cited by
- 812
- References
- 71
- FWCI
- 39.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.